Cytokinetics, Inc. (CYTK)

NASDAQ: CYTK · IEX Real-Time Price · USD
39.35
-2.81 (-6.65%)
May 18, 2022 12:16 PM EDT - Market open
Market Cap3.37B
Revenue (ttm)65.03M
Net Income (ttm)-257.66M
Shares Out85.65M
EPS (ttm)-2.80
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume269,718
Open41.02
Previous Close42.15
Day's Range39.21 - 42.16
52-Week Range17.72 - 47.90
Beta1.36
AnalystsBuy
Price Target60.01 (+52.5%)
Earnings DateMay 4, 2022

About CYTK

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase II...

IndustryBiotechnology
IPO DateApr 29, 2004
CEORobert Blum
Employees253
Stock ExchangeNASDAQ
Ticker SymbolCYTK
Full Company Profile

Financial Performance

In 2021, Cytokinetics's revenue was $70.43 million, an increase of 26.15% compared to the previous year's $55.83 million. Losses were -$215.31 million, 69.2% more than in 2020.

Financial Statements

Analyst Forecast

According to 19 analysts, the average rating for CYTK stock is "Buy." The 12-month stock price forecast is 60.01, which is an increase of 52.52% from the latest price.

Price Target
$60.01
(52.52% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Cytokinetics and the ALS Association Renew Partnership to Advance the Fight Against ALS

SOUTH SAN FRANCISCO, Calif., AND WASHINGTON, May 18, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) and The ALS Association today announced the continuation of their partnership in t...

4 hours ago - GlobeNewsWire

Cytokinetics to Participate in the 2022 H.C. Wainwright Global Life Sciences Conference

SOUTH SAN FRANCISCO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to presen...

20 hours ago - GlobeNewsWire

Cytokinetics Provides Regulatory Update Related to New Drug Application for Omecamtiv Mecarbil

FDA Plans to Convene Advisory Committee Meeting FDA Plans to Convene Advisory Committee Meeting

1 day ago - GlobeNewsWire

Cytokinetics Announces Three Upcoming Presentations at the European Society of Cardiology Heart Failure 2022 Congress

SOUTH SAN FRANCISCO, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three Late-Breaking Science presentations at Heart Failure 2022, an International ...

1 day ago - GlobeNewsWire

Mizuho: these two biotech stocks are worth buying right now

Biotech is one of the hardest hit sectors this year, with the SPDR S&P Biotech ETF now down 45% year-to-date. Still, a Mizuho analyst says the following two stocks are worth buying.

Other symbols:GILD
1 week ago - Invezz

Cytokinetics (CYTK) Reports Q1 Loss, Misses Revenue Estimates

Cytokinetics (CYTK) delivered earnings and revenue surprises of -9.68% and 77.53%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

Cytokinetics Reports First Quarter 2022 Financial Results

Initial Data from REDWOOD-HCM OLE, the Open Label Extension Study of Aficamten,  to be Presented at Heart Failure 2022 on May 23, 2022

1 week ago - GlobeNewsWire

Cytokinetics to Hold Annual Meeting of Stockholders

SOUTH SAN FRANCISCO, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that its Annual Meeting of Stockholders will be held on Tuesday, May 10, 2022 at 1...

2 weeks ago - GlobeNewsWire

Strength Seen in Cytokinetics (CYTK): Can Its 11.5% Jump Turn into More Strength?

Cytokinetics (CYTK) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the ...

2 weeks ago - Zacks Investment Research

Cytokinetics to Announce First Quarter Results on May 4, 2022

SOUTH SAN FRANCISCO, Calif., April 20, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report first quarter results on May 4, 2022 at 4:00 PM E...

3 weeks ago - GlobeNewsWire

Cytokinetics Announces Changes to Board of Directors

L. Patrick Gage, Ph.D. to Retire from Board

1 month ago - GlobeNewsWire

Cytokinetics to Participate in the 21st Annual Needham Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., April 06, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to part...

1 month ago - GlobeNewsWire

Cytokinetics Announces Results From METEORIC-HF and Additional Data From GALACTIC-HF Presented at the American Colleg...

No Effect of Omecamtiv Mecarbil On Exercise Capacity in Patients with Heart Failure with Reduced Ejection Fraction in METEORIC-HF

1 month ago - GlobeNewsWire

Cytokinetics Announces Results From Cohort 3 of Redwood-HCM Presented at American College of Cardiology 71st Annual S...

Aficamten Reduced LVOT Gradients and Improved NYHA Class and NT-proBNP in Patients with Obstructive Hypertrophic Cardiomyopathy Treated with Disopyramide Aficamten Reduced LVOT Gradients and Improved NY...

1 month ago - GlobeNewsWire

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on March 31, 2022 it granted stock options to purchase an aggregate of 165,...

1 month ago - GlobeNewsWire

Cytokinetics Announces Four Upcoming Presentations at the American College of Cardiology 71st Annual Scientific Sessi...

SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced four presentations at the American College of Cardiology 71st Annual Scientific ...

1 month ago - GlobeNewsWire

Cytokinetics to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to pres...

2 months ago - GlobeNewsWire

Cytokinetics Announces Cohort 4 of REDWOOD-HCM Is Open to Enrollment

Cohort 4 to Enroll Patients with Non-Obstructive Hypertrophic Cardiomyopathy Cohort 4 to Enroll Patients with Non-Obstructive Hypertrophic Cardiomyopathy

2 months ago - GlobeNewsWire

Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is joining the European Organisation for Rare Diseases (EURORDIS) and the...

2 months ago - GlobeNewsWire

Cytokinetics (CYTK) Reports Q4 Loss, Tops Revenue Estimates

Cytokinetics (CYTK) delivered earnings and revenue surprises of 59.55% and 931.54%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Cytokinetics Reports Fourth Quarter 2021 Financial Results

Commercial Launch Readiness Activities Underway for Omecamtiv Mecarbil  in Advance of PDUFA Date of November 30, 2022

2 months ago - GlobeNewsWire

Cytokinetics Announces Start of SEQUOIA-HCM, a Phase 3 Clinical Trial of Aficamten in Patients With Symptomatic Obstr...

Pivotal Trial to Assess the Potential of Aficamten to Improve Exercise Capacity, Heart Failure Symptoms and Functional Class Pivotal Trial to Assess the Potential of Aficamten to Improve Exercise Capaci...

2 months ago - GlobeNewsWire

Analysts Estimate Cytokinetics (CYTK) to Report a Decline in Earnings: What to Look Out for

Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

Cytokinetics and the American Heart Association Bay Area Announce a Three-Year Collaboration to Advance Education and...

SOUTH SAN FRANCISCO, Calif. and OAKLAND, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) and the American Heart Association (AHA) Bay Area today announced a three-yea...

3 months ago - GlobeNewsWire

Cytokinetics Announces Topline Results From METEORIC-HF

No Effect of Omecamtiv Mecarbil On Exercise Capacity in Patients with Heart Failure with Reduced Ejection Fraction

3 months ago - GlobeNewsWire